創勝集團-B(06628.HK):TST002在治療骨質疏鬆的中國I期研究成功完成首例患者給藥
格隆匯4月28日丨創勝集團-B(06628.HK)發佈公告,TST002在治療骨質疏鬆的中國I期研究成功完成首例患者給藥。此次I期臨牀試驗爲一項隨機雙盲、安慰劑對照、單次給藥、劑量遞增的多中心研究,旨在評估TST002用於骨質疏鬆患者治療的安全性、耐受性及藥物代謝動力學特徵。
集團執行副總裁、全球研發負責人兼首席醫學官石博士表示:“TST002有望成爲全球第二款硬骨抑素靶點的單抗,我們期待深入的研究,進一步評估TST002的安全性和耐受性,爲我國骨質疏鬆患者帶來更加高效及多元化的治療方案。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.